IPO News | Legend Biotech (LEGN.US) Reportedly Considering Second Listing Outside US, Hong Kong Among Potential Locations

Stock News

Sep 08

According to reports, Legend Biotech (LEGN.US) is considering a second listing outside the United States due to strong investor interest in pharmaceutical companies. Sources familiar with the matter indicate that potential listing locations include Hong Kong, Singapore, and London. A second listing in Hong Kong, in particular, could help boost Legend Biotech's valuation. The report notes that Legend Biotech is still in the consideration phase and may decide not to proceed with a second listing. Representatives from Legend Biotech declined to comment.

Legend Biotech was founded in 2014 and went public on the US NASDAQ in 2020. The company specializes in CAR-T cell immunotherapy for cancer treatment, with its flagship product ciltacabtagene autoleucel already approved by the US FDA for market.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1161475716"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1161475716\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1161475716?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-08 10:12","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1161475716","market":"nz","top_or_hot":-1,"title":"IPO News | Legend Biotech (LEGN.US) Reportedly Considering Second Listing Outside US, Hong Kong Among Potential Locations","media":"Stock News","content":"<p>According to reports, Legend Biotech (LEGN.US) is considering a second listing outside the United States due to strong investor interest in pharmaceutical companies. Sources familiar with the matter indicate that potential listing locations include Hong Kong, Singapore, and London. A second listing in Hong Kong, in particular, could help boost Legend Biotech's valuation. The report notes that Legend Biotech is still in the consideration phase and may decide not to proceed with a second listing. Representatives from Legend Biotech declined to comment.</p>\n<p>Legend Biotech was founded in 2014 and went public on the US NASDAQ in 2020. The company specializes in CAR-T cell immunotherapy for cancer treatment, with its flagship product ciltacabtagene autoleucel already approved by the US FDA for market.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>IPO News | Legend Biotech (LEGN.US) Reportedly Considering Second Listing Outside US, Hong Kong Among Potential Locations</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIPO News | Legend Biotech (LEGN.US) Reportedly Considering Second Listing Outside US, Hong Kong Among Potential Locations\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-09-08 10:12</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>According to reports, Legend Biotech (LEGN.US) is considering a second listing outside the United States due to strong investor interest in pharmaceutical companies. Sources familiar with the matter indicate that potential listing locations include Hong Kong, Singapore, and London. A second listing in Hong Kong, in particular, could help boost Legend Biotech's valuation. The report notes that Legend Biotech is still in the consideration phase and may decide not to proceed with a second listing. Representatives from Legend Biotech declined to comment.</p>\n<p>Legend Biotech was founded in 2014 and went public on the US NASDAQ in 2020. The company specializes in CAR-T cell immunotherapy for cancer treatment, with its flagship product ciltacabtagene autoleucel already approved by the US FDA for market.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"","article_id":"1161475716","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1161475716","pubTimestamp":1757297537,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"According to reports, Legend Biotech (LEGN.US) is considering a second listing outside the United States due to strong investor interest in pharmaceutical companies. Sources familiar with the matter...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","BK4585":"ETF&股票定投概念","LEGN":"传奇生物","BK4588":"碎股","BK4505":"高瓴资本持仓"},"translate_title":"IPO快讯|传奇生物(LEGN.US)据报道考虑在美国、香港以外的潜在地点进行第二次上市","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LEGN":1},"content_text":"According to reports, Legend Biotech (LEGN.US) is considering a second listing outside the United States due to strong investor interest in pharmaceutical companies. Sources familiar with the matter indicate that potential listing locations include Hong Kong, Singapore, and London. A second listing in Hong Kong, in particular, could help boost Legend Biotech's valuation. The report notes that Legend Biotech is still in the consideration phase and may decide not to proceed with a second listing. Representatives from Legend Biotech declined to comment.\nLegend Biotech was founded in 2014 and went public on the US NASDAQ in 2020. The company specializes in CAR-T cell immunotherapy for cancer treatment, with its flagship product ciltacabtagene autoleucel already approved by the US FDA for market.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}